Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia
- PMID: 28709770
- PMCID: PMC5745291
- DOI: 10.1016/j.schres.2017.07.009
Meta-analysis of mismatch negativity to simple versus complex deviants in schizophrenia
Abstract
Mismatch negativity (MMN) deficits in schizophrenia (SCZ) have been studied extensively since the early 1990s, with the vast majority of studies using simple auditory oddball task deviants that vary in a single acoustic dimension such as pitch or duration. There has been a growing interest in using more complex deviants that violate more abstract rules to probe higher order cognitive deficits. It is still unclear how sensory processing deficits compare to and contribute to higher order cognitive dysfunction, which can be investigated with later attention-dependent auditory event-related potential (ERP) components such as a subcomponent of P300, P3b. In this meta-analysis, we compared MMN deficits in SCZ using simple deviants to more complex deviants. We also pooled studies that measured MMN and P3b in the same study sample and examined the relationship between MMN and P3b deficits within study samples. Our analysis reveals that, to date, studies using simple deviants demonstrate larger deficits than those using complex deviants, with effect sizes in the range of moderate to large. The difference in effect sizes between deviant types was reduced significantly when accounting for magnitude of MMN measured in healthy controls. P3b deficits, while large, were only modestly greater than MMN deficits (d=0.21). Taken together, our findings suggest that MMN to simple deviants may still be optimal as a biomarker for SCZ and that sensory processing dysfunction contributes significantly to MMN deficit and disease pathophysiology.
Keywords: Complex deviant; Meta-analysis; Mismatch negativity; P300; P3b; Schizophrenia.
Copyright © 2017 Elsevier B.V. All rights reserved.
Conflict of interest statement
Dr. Javitt reports having received consulting payments within the last 36 months from Sunovion, Forum, and Takeda. He has received research support from Roche. He holds intellectual property rights for use of NMDA modulators in treatment of neuropsychiatric disorders. He holds equity in Glytech, AASI, and NeuroRX, and serves on the advisory board of Promentis and NeuroRx. All other co-authors report no conflicts.
Figures
References
-
- Alain C, Hargrave R, Woods DL. Processing of auditory stimuli during visual attention in patients with schizophrenia. Biol. Psychiatry. 1998;44(11):1151–1159. - PubMed
-
- Atkinson RJ, Michie PT, Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol. Psychiatry. 2012;71(2):98–104. - PubMed
-
- Baldeweg T, Hirsch SR. Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: a comparison with bipolar disorder and Alzheimer’s disease. Int. J. Psychophysiol. 2015;95(2):145–155. - PubMed
-
- Baldeweg T, Klugman A, Gruzelier J, Hirsch SR. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr. Res. 2004;69(2):203–217. - PubMed
-
- Baldeweg T, Klugman A, Gruzelier JH, Hirsch SR. Impairment in frontal but not temporal components of mismatch negativity in schizophrenia. Int. J. Psychophysiol. 2002;43(2):111–122. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
